Granite FO LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

Granite FO LLC’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.87K	Hold	3	–	–	﹤0.01%	146
2026 Q1	$2.32K	Hold	3	–	–	﹤0.01%	139
2025 Q4	$2.32K	Hold	3	–	–	﹤0.01%	146
2025 Q3	$1.69K	Hold	3	–	–	﹤0.01%	172
2025 Q2	$1.57K	Hold	3	–	–	﹤0.01%	171
2025 Q1	$1.9K	Hold	3	–	–	﹤0.01%	161
2024 Q4	$2.14K	Sell	3 -850	-100%	-$713K	﹤0.01%	157
2024 Q3	$897K	Buy	853 +3	+0.4%	+$3.34K	0.51%	26
2024 Q2	$893K	Sell	850 -3	-0.4%	-$2.91K	0.57%	25
2024 Q1	$1.02M	Buy	853 +3	+0.4%	+$2.85K	0.6%	24
2023 Q4	$747K	Hold	850	–	–	0.5%	27
2023 Q3	$700K	Hold	850	–	–	0.49%	27
2023 Q2	$611K	Sell	850 -150	-15%	-$116K	0.42%	30
2023 Q1	$802K	Sell	1,000 -440	-31%	-$332K	0.49%	30
2022 Q4	$1.08M	Buy	+1,440	New	+$1.06M	0.83%	18

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Granite FO LLC's REGN Position: Q2 2026 in Review

Granite FO LLC held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 3 shares worth $1.87K. The position accounts for ﹤0.01% of the portfolio, ranked #146.

Granite FO LLC first reported a position in REGN in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.08M in Q4 2022. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Granite FO LLC held 3 shares of Regeneron Pharmaceuticals worth $1.87K as of Q2 2026.
Granite FO LLC left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of Granite FO LLC's portfolio in Q2 2026, its #146 holding.
Granite FO LLC first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
Granite FO LLC's Regeneron Pharmaceuticals position peaked at $1.08M in Q4 2022.
1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Granite FO LLC's 13F filing for Q2 2026, filed 15 Jul 2026.